Pulmonary hypertension (PH) is a heterogeneous and life-threatening cardiopulmonary disorder in which mitochondrial dysfunction is believed to drive pathogenesis, although the underlying mechanisms remain unclear. To determine if abnormal SIRT3 (sirtuin 3) activity is related to mitochondrial dysfunction in adventitial fibroblasts from patients with idiopathic pulmonary arterial hypertension (IPAH) and hypoxic PH calves (PH-Fibs) and whether SIRT3 could be a potential therapeutic target to improve mitochondrial function, SIRT3 concentrations in control fibroblasts, PH-Fibs, and lung tissues were determined using quantitative real-time PCR and western blot. SIRT3 deacetylase activity in cells and lung tissues was determined using western blot, immunohistochemistry staining, and immunoprecipitation. Glycolysis and mitochondrial function in fibroblasts were measured using respiratory analysis and fluorescence-lifetime imaging microscopy. The effects of restoring SIRT3 activity (by overexpression of SIRT3 with plasmid, activation SIRT3 with honokiol, and supplementation with the SIRT3 cofactor nicotinamide adenine dinucleotide [NAD+]) on mitochondrial protein acetylation, mitochondrial function, cell proliferation, and gene expression in PH-Fibs were also investigated. We found that SIRT3 concentrations were decreased in PH-Fibs and PH lung tissues, and its cofactor, NAD+, was also decreased in PH-Fibs. Increased acetylation in overall mitochondrial proteins and SIRT3-specific targets (MPC1 [mitochondrial pyruvate carrier 1] and MnSOD2 [mitochondrial superoxide dismutase]), as well as decreased MnSOD2 activity, was identified in PH-Fibs and PH lung tissues. Normalization of SIRT3 activity, by increasing its expression with plasmid or with honokiol and supplementation with its cofactor NAD+, reduced mitochondrial protein acetylation, improved mitochondrial function, inhibited proliferation, and induced apoptosis in PH-Fibs. Thus, our study demonstrated that restoration of SIRT3 activity in PH-Fibs can reduce mitochondrial protein acetylation and restore mitochondrial function and PH-Fib phenotype in PH.

Cardiovascular Pulmonary Research Laboratories Departments of Pediatrics and Medicine

Department of Craniofacial Biology and

Division of Pulmonary and Critical Care Medicine Department of Medicine University of Colorado Anschutz Medical Campus Aurora Colorado; and

Laboratory of Pancreatic Islet Research Institute of Physiology Czech Academy of Sciences Prague Czech Republic

Section of Neonatology Department of Pediatrics

Komentář v

Am J Respir Cell Mol Biol. 2023 Nov;69(5):497-499. doi: 10.1165/rcmb.2023-0199ED. PubMed

Zobrazit více v PubMed

Lau EMT, Giannoulatou E, Celermajer DS, Humbert M. Epidemiology and treatment of pulmonary arterial hypertension. Nat Rev Cardiol . 2017;14:603–614. PubMed

D’Alessandro A, El Kasmi KC, Plecitá-Hlavatá L, Ježek P, Li M, Zhang H, et al. Hallmarks of pulmonary hypertension: mesenchymal and inflammatory cell metabolic reprogramming. Antioxid Redox Signal . 2018;28:230–250. PubMed PMC

Li M, Riddle S, Zhang H, D’Alessandro A, Flockton A, Serkova NJ, et al. Metabolic reprogramming regulates the proliferative and inflammatory phenotype of adventitial fibroblasts in pulmonary hypertension through the transcriptional corepressor C-terminal binding protein-1. Circulation . 2016;134:1105–1121. PubMed PMC

Stenmark KR, Tuder RM, El Kasmi KC. Metabolic reprogramming and inflammation act in concert to control vascular remodeling in hypoxic pulmonary hypertension. J Appl Physiol (1985) . 2015;119:1164–1172. PubMed PMC

Plecitá-Hlavatá L, Tauber J, Li M, Zhang H, Flockton AR, Pullamsetti SS, et al. Constitutive reprogramming of fibroblast mitochondrial metabolism in pulmonary hypertension. Am J Respir Cell Mol Biol . 2016;55:47–57. PubMed PMC

Paulin R, Michelakis ED. The metabolic theory of pulmonary arterial hypertension. Circ Res . 2014;115:148–164. PubMed

Dasgupta A, Wu D, Tian L, Xiong PY, Dunham-Snary KJ, Chen KH, et al. Mitochondria in the pulmonary vasculature in health and disease: oxygen-sensing, metabolism, and dynamics. Compr Physiol . 2020;10:713–765. PubMed

Ryan JJ, Archer SL. Emerging concepts in the molecular basis of pulmonary arterial hypertension: part I: metabolic plasticity and mitochondrial dynamics in the pulmonary circulation and right ventricle in pulmonary arterial hypertension. Circulation . 2015;131:1691–1702. PubMed PMC

Xu W, Janocha AJ, Erzurum SC. Metabolism in pulmonary hypertension. Annu Rev Physiol . 2021;83:551–576. PubMed PMC

Pullamsetti SS, Mamazhakypov A, Weissmann N, Seeger W, Savai R. Hypoxia-inducible factor signaling in pulmonary hypertension. J Clin Invest . 2020;130:5638–5651. PubMed PMC

Rahman J, Singh P, Merle NS, Niyonzima N, Kemper C. Complement’s favourite organelle—mitochondria? Br J Pharmacol . 2021;178:2771–2785. PubMed PMC

Srinivasan K, Pandey AK, Livingston A, Venkatesh S. Roles of host mitochondria in the development of COVID-19 pathology: could mitochondria be a potential therapeutic target? Mol Biomed . 2021;2:38. PubMed PMC

Sun X, Lu Q, Yegambaram M, Kumar S, Qu N, Srivastava A, et al. TGF-β1 attenuates mitochondrial bioenergetics in pulmonary arterial endothelial cells via the disruption of carnitine homeostasis. Redox Biol . 2020;36:101593. PubMed PMC

Archer SL, Marsboom G, Kim GH, Zhang HJ, Toth PT, Svensson EC, et al. Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation . 2010;121:2661–2671. PubMed PMC

Napoli C, Benincasa G, Loscalzo J. Epigenetic inheritance underlying pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol . 2019;39:653–664. PubMed PMC

Culley MK, Chan SY. Mitochondrial metabolism in pulmonary hypertension: beyond mountains there are mountains. J Clin Invest . 2018;128:3704–3715. PubMed PMC

Zhang H, Wang D, Li M, Plecitá-Hlavatá L, D’Alessandro A, Tauber J, et al. Metabolic and proliferative state of vascular adventitial fibroblasts in pulmonary hypertension is regulated through a microRNA-124/PTBP1 (polypyrimidine tract binding protein 1)/pyruvate kinase muscle axis. Circulation . 2017;136:2468–2485. PubMed PMC

McMurtry MS, Bonnet S, Wu X, Dyck JR, Haromy A, Hashimoto K, et al. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res . 2004;95:830–840. PubMed

Michelakis ED, Gurtu V, Webster L, Barnes G, Watson G, Howard L, et al. Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. Sci Transl Med . 2017;9:eaao4583. PubMed

Cao M, Zhao Q, Sun X, Qian H, Lyu S, Chen R, et al. Sirtuin 3: emerging therapeutic target for cardiovascular diseases. Free Radic Biol Med . 2022;180:63–74. PubMed

Liu Y, Shen X, Pang M, Sun Z, Qian Y, Xue W, et al. Role of histone deacetylase Sirt3 in the development and regression of atherosclerosis. Life Sci . 2021;272:119178. PubMed

Bernal-Ramírez J, Silva-Platas C, Jerjes-Sánchez C, Ramos-González MR, Vázquez-Garza E, Chapoy-Villanueva H, et al. Resveratrol prevents right ventricle dysfunction, calcium mishandling, and energetic failure via SIRT3 stimulation in pulmonary arterial hypertension. Oxid Med Cell Longev . 2021;2021:9912434. PubMed PMC

Paulin R, Dromparis P, Sutendra G, Gurtu V, Zervopoulos S, Bowers L, et al. Sirtuin 3 deficiency is associated with inhibited mitochondrial function and pulmonary arterial hypertension in rodents and humans. Cell Metab . 2014;20:827–839. PubMed

Lajoie AC, Potus F. Sirtuin 3 and uncouplin protein 2, the missing link between genetics, metabolism, and pulmonary arterial hypertension. J Am Heart Assoc . 2021;10:e023065. PubMed PMC

Colloca A, Balestrieri A, Anastasio C, Balestrieri ML, D’Onofrio N. Mitochondrial sirtuins in chronic degenerative diseases: new metabolic targets in colorectal cancer. Int J Mol Sci . 2022;23:3212. PubMed PMC

Jing E, O’Neill BT, Rardin MJ, Kleinridders A, Ilkeyeva OR, Ussar S, et al. Sirt3 regulates metabolic flexibility of skeletal muscle through reversible enzymatic deacetylation. Diabetes . 2013;62:3404–3417. PubMed PMC

Peugnet V, Chwastyniak M, Mulder P, Lancel S, Bultot L, Fourny N, et al. Mitochondrial-targeted therapies require mitophagy to prevent oxidative stress induced by SOD2 inactivation in hypertrophied cardiomyocytes. Antioxidants . 2022;11:723. PubMed PMC

Rehan M, Kurundkar D, Kurundkar AR, Logsdon NJ, Smith SR, Chanda D, et al. Restoration of SIRT3 gene expression by airway delivery resolves age-associated persistent lung fibrosis in mice. Nat Aging . 2021;1:205–217. PubMed PMC

Zhang Y, Gong W, Xu M, Zhang S, Shen J, Zhu M, et al. Necroptosis inhibition by hydrogen sulfide alleviated hypoxia-induced cardiac fibroblasts proliferation via sirtuin 3. Int J Mol Sci . 2021;22:11893. PubMed PMC

Xu C, Han J, Jia D, Cai J, Yuan J, Ge X. SIRT3 confers protection against acute pulmonary embolism by anti-inflammation, anti-oxidative stress, anti-apoptosis: participation of AMPK/mTOR pathway. Exp Anim . 2023 doi: 10.1538/expanim.22-0175. PubMed DOI PMC

Bao J, Lu Z, Joseph JJ, Carabenciov D, Dimond CC, Pang L, et al. Characterization of the murine SIRT3 mitochondrial localization sequence and comparison of mitochondrial enrichment and deacetylase activity of long and short SIRT3 isoforms. J Cell Biochem . 2010;110:238–247. PubMed PMC

Bricker DK, Taylor EB, Schell JC, Orsak T, Boutron A, Chen YC, et al. A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans. Science . 2012;337:96–100. PubMed PMC

Liang L, Li Q, Huang L, Li D, Li X. Sirt3 binds to and deacetylates mitochondrial pyruvate carrier 1 to enhance its activity. Biochem Biophys Res Commun . 2015;468:807–812. PubMed

Ji Z, Liu GH, Qu J. Mitochondrial sirtuins, metabolism, and aging. J Genet Genomics . 2022;49:287–298. PubMed

Li M, Riddle SR, Frid MG, El Kasmi KC, McKinsey TA, Sokol RJ, et al. Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension. J Immunol . 2011;187:2711–2722. PubMed PMC

Bock FJ, Tait SWG. Mitochondria as multifaceted regulators of cell death. Nat Rev Mol Cell Biol . 2020;21:85–100. PubMed

Di LJ, Byun JS, Wong MM, Wakano C, Taylor T, Bilke S, et al. Genome-wide profiles of CtBP link metabolism with genome stability and epithelial reprogramming in breast cancer. Nat Commun . 2013;4:1449. PubMed PMC

Zhao L, Ashek A, Wang L, Fang W, Dabral S, Dubois O, et al. Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments. Circulation . 2013;128:1214–1224. PubMed

Iqbal M, Cawthon D, Wideman RF, Jr, Bottje WG. Lung mitochondrial dysfunction in pulmonary hypertension syndrome. I. Site-specific defects in the electron transport chain. Poult Sci . 2001;80:485–495. PubMed

Sharp J, Farha S, Park MM, Comhair SA, Lundgrin EL, Tang WH, et al. Coenzyme Q supplementation in pulmonary arterial hypertension. Redox Biol . 2014;2:884–891. PubMed PMC

Zhang Y, Zervopoulos SD, Boukouris AE, Lorenzana-Carrillo MA, Saleme B, Webster L, et al. SNPs for genes encoding the mitochondrial proteins sirtuin3 and uncoupling protein 2 are associated with disease severity, type 2 diabetes, and outcomes in patients with pulmonary arterial hypertension and this is recapitulated in a new mouse model lacking both genes. J Am Heart Assoc . 2021;10:e020451. PubMed PMC

Jia Z, Yan H, Wang S, Wang L, Cao Y, Lin S, et al. Shufeiya recipe improves monocrotaline-induced pulmonary hypertension in rats by regulating SIRT3/FOXO3a and its downstream signaling pathways. Dis Markers . 2022;2022:3229888. PubMed PMC

Waypa GB, Osborne SW, Marks JD, Berkelhamer SK, Kondapalli J, Schumacker PT. Sirtuin 3 deficiency does not augment hypoxia-induced pulmonary hypertension. Am J Respir Cell Mol Biol . 2013;49:885–891. PubMed PMC

Stenmark KR, Nozik-Grayck E, Gerasimovskaya E, Anwar A, Li M, Riddle S, et al. The adventitia: essential role in pulmonary vascular remodeling. Compr Physiol . 2011;1:141–161. PubMed PMC

Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature . 2000;403:795–800. PubMed

Cambronne XA, Stewart ML, Kim D, Jones-Brunette AM, Morgan RK, Farrens DL, et al. Biosensor reveals multiple sources for mitochondrial NAD+ Science . 2016;352:1474–1477. PubMed PMC

Verdin E. The many faces of sirtuins: coupling of NAD metabolism, sirtuins and lifespan. Nat Med . 2014;20:25–27. PubMed

Yoshino J, Baur JA, Imai SI. Nad(+) intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab . 2018;27:513–528. PubMed PMC

Grootaert MOJ, Bennett MR. Sirtuins in atherosclerosis: guardians of healthspan and therapeutic targets. Nat Rev Cardiol . 2022;19:668–683. PubMed

Kong X, Wang R, Xue Y, Liu X, Zhang H, Chen Y, et al. Sirtuin 3, a new target of PGC-1alpha, plays an important role in the suppression of ROS and mitochondrial biogenesis. PLoS ONE . 2010;5:e11707. PubMed PMC

Giralt A, Hondares E, Villena JA, Ribas F, Díaz-Delfín J, Giralt M, et al. Peroxisome proliferator-activated receptor-gamma coactivator-1alpha controls transcription of the Sirt3 gene, an essential component of the thermogenic brown adipocyte phenotype. J Biol Chem . 2011;286:16958–16966. PubMed PMC

Kwon S, Seok S, Yau P, Li X, Kemper B, Kemper JK. Obesity and aging diminish sirtuin 1 (SIRT1)-mediated deacetylation of SIRT3, leading to hyperacetylation and decreased activity and stability of SIRT3. J Biol Chem . 2017;292:17312–17323. PubMed PMC